These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 29668117)

  • 21. Diagnosis and Treatment of Venous Malformations. Consensus Document of the International Union of Phlebology (IUP): updated 2013.
    Lee BB; Baumgartner I; Berlien P; Bianchini G; Burrows P; Gloviczki P; Huang Y; Laredo J; Loose DA; Markovic J; Mattassi R; Parsi K; Rabe E; Rosenblatt M; Shortell C; Stillo F; Vaghi M; Villavicencio L; Zamboni P;
    Int Angiol; 2015 Apr; 34(2):97-149. PubMed ID: 24566499
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic Basis and Therapies for Vascular Anomalies.
    Queisser A; Seront E; Boon LM; Vikkula M
    Circ Res; 2021 Jun; 129(1):155-173. PubMed ID: 34166070
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Venous malformations: PIK3CA mutations guide new treatments.
    Dbouk HA
    Oncotarget; 2016 Aug; 7(31):48852-48853. PubMed ID: 27447853
    [No Abstract]   [Full Text] [Related]  

  • 24. Efficacy and Safety of Mammalian Target of Rapamycin Inhibitors in Vascular Anomalies: A Systematic Review.
    Nadal M; Giraudeau B; Tavernier E; Jonville-Bera AP; Lorette G; Maruani A
    Acta Derm Venereol; 2016 May; 96(4):448-52. PubMed ID: 26607948
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Disorganized vascular structures in sporadic venous malformations: a possible correlation with balancing effect between Tie2 and TGF-β.
    Chen G; Ren JG; Zhang W; Sun YF; Wang FQ; Li RF; Zhang J; Zhao YF
    Sci Rep; 2014 Jun; 4():5457. PubMed ID: 24966004
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association study between of Tie2/angiopoietin-2 and VEGF/KDR pathway gene polymorphisms and vascular malformations.
    Zheng Q; Du J; Zhang Z; Xu J; Fu L; Cao Y; Huang X; Guo L
    Gene; 2013 Jul; 523(2):195-8. PubMed ID: 23566851
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Somatic PIK3CA mutations as a driver of sporadic venous malformations.
    Castel P; Carmona FJ; Grego-Bessa J; Berger MF; Viale A; Anderson KV; Bague S; Scaltriti M; Antonescu CR; Baselga E; Baselga J
    Sci Transl Med; 2016 Mar; 8(332):332ra42. PubMed ID: 27030594
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Constitutively active PIK3CA mutations are expressed by lymphatic and vascular endothelial cells in capillary lymphatic venous malformation.
    Le Cras TD; Goines J; Lakes N; Pastura P; Hammill AM; Adams DM; Boscolo E
    Angiogenesis; 2020 Aug; 23(3):425-442. PubMed ID: 32350708
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Functional analysis of a mutant form of the receptor tyrosine kinase Tie2 causing venous malformations.
    Morris PN; Dunmore BJ; Tadros A; Marchuk DA; Darland DC; D'Amore PA; Brindle NP
    J Mol Med (Berl); 2005 Jan; 83(1):58-63. PubMed ID: 15526080
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeted therapy for capillary-venous malformations.
    Zerbib L; Ladraa S; Fraissenon A; Bayard C; Firpion M; Venot Q; Protic S; Hoguin C; Thomas A; Fraitag S; Duong JP; Kaltenbach S; Balducci E; Lefevre C; Villarese P; Asnafi V; Broissand C; Goudin N; Nemazanyy I; Autret G; Tavitian B; Legendre C; Arzouk N; Minard-Colin V; Chopinet C; Dussiot M; Adams DM; Mirault T; Guibaud L; Isenring P; Canaud G
    Signal Transduct Target Ther; 2024 Jun; 9(1):146. PubMed ID: 38880808
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In pursuit of synergy: An investigation of the PI3K/mTOR/MEK co-targeted inhibition strategy in NSCLC.
    Heavey S; Cuffe S; Finn S; Young V; Ryan R; Nicholson S; Leonard N; McVeigh N; Barr M; O'Byrne K; Gately K
    Oncotarget; 2016 Nov; 7(48):79526-79543. PubMed ID: 27765909
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The genetics of vascular birthmarks.
    Mahajan P; Bergstrom KL; Phung TL; Metry DW
    Clin Dermatol; 2022; 40(4):313-321. PubMed ID: 35181412
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mutant Tie2 causing venous malformation signals through Shc.
    Morris PN; Dunmore BJ; Brindle NP
    Biochem Biophys Res Commun; 2006 Jul; 346(1):335-8. PubMed ID: 16756945
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2.
    Vikkula M; Boon LM; Carraway KL; Calvert JT; Diamonti AJ; Goumnerov B; Pasyk KA; Marchuk DA; Warman ML; Cantley LC; Mulliken JB; Olsen BR
    Cell; 1996 Dec; 87(7):1181-90. PubMed ID: 8980225
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vascular anomalies of the head and neck: a review of genetics.
    Yadav P; De Castro DK; Waner M; Meyer L; Fay A
    Semin Ophthalmol; 2013; 28(5-6):257-66. PubMed ID: 24010650
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A narrative review of the role of sirolimus in the treatment of congenital vascular malformations.
    Geeurickx M; Labarque V
    J Vasc Surg Venous Lymphat Disord; 2021 Sep; 9(5):1321-1333. PubMed ID: 33737259
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human iPSC and CRISPR targeted gene knock-in strategy for studying the somatic TIE2
    Lazovic B; Nguyen HT; Ansarizadeh M; Wigge L; Kohl F; Li S; Carracedo M; Kettunen J; Krimpenfort L; Elgendy R; Richter K; De Silva L; Bilican B; Singh P; Saxena P; Jakobsson L; Hong X; Eklund L; Hicks R
    Angiogenesis; 2024 Aug; 27(3):523-542. PubMed ID: 38771392
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Xenograft Model for Venous Malformation.
    Goines J; Boscolo E
    Methods Mol Biol; 2021; 2206():179-192. PubMed ID: 32754818
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Constitutive Active Mutant TIE2 Induces Enlarged Vascular Lumen Formation with Loss of Apico-basal Polarity and Pericyte Recruitment.
    Cai Y; Schrenk S; Goines J; Davis GE; Boscolo E
    Sci Rep; 2019 Aug; 9(1):12352. PubMed ID: 31451744
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Single-center experience with sirolimus therapy for vascular malformations.
    Yesil S; Tanyildiz HG; Bozkurt C; Cakmakci E; Sahin G
    Pediatr Hematol Oncol; 2016 Apr; 33(3):219-25. PubMed ID: 27128161
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.